

**State of Wisconsin Department of Safety
and Professional Services**

4822 Madison Yards Way, PO Box 8366,
Madison, WI 53708-8366



608.266.2112 | 877.617.1565
safety.wi.gov

Tony Evers, Governor
Dan Hereth, Secretary

**VIRTUAL/TELECONFERENCE
PHARMACY EXAMINING BOARD**
Virtual, 4822 Madison Yards Way, , Madison
Contact: Brad Wojciechowski (608) 266-2112
October 15, 2026

The following agenda describes the issues that the Board, plans to consider at the meeting. At the time of the meeting, items may be removed from the agenda. Please consult the meeting minutes for a record of the actions of the Board.

AGENDA

11:00 A.M.

OPEN SESSION – CALL TO ORDER – ROLL CALL

A. Adoption of Agenda (1-4)

B. Approval of Minutes of August 13, 2026 (5-10)

C. Introductions, Announcements and Recognition

1. Introductions:
 - a. Etan Maistelman, Pharmacist Member (Succeeds: Weitekamp)
 - b. Jennifer Marano, Pharmacy Technician Member
 - c. Alexander Prince, Pharmacy Technician Member

D. Reminders: Conflicts of Interest, Scheduling Concerns

E. Administrative Matters – Discussion and Consideration

1. Department, Staff and Board Updates
2. Appointment of Liaisons and Alternates
3. Board Members – Term Expiration Dates
 - a. Esser, Paul T. – 7/1/2029
 - b. Maistelman, Etan – 7/1/2030
 - c. Marano, Jennifer – 7/1/2030
 - d. O'Hagan, Tiffany M. – 7/1/2028
 - e. Peterangelo, Anthony – 7/1/2027
 - f. Prince, Alexander 7/1/2030
 - g. Sokn, Erick M. – 7/1/2026
 - h. Wilson, Christa M. – 7/1/2029

F. Administrative Rule Matters – Discussion and Consideration (11-16)

1. Scope Statement:
 - a. Phar 1 and 6, Relating to Facilities, Floor Design, and Remodeling **(12-13)**

- b. Phar 1 and 12 to 14, Relating to Licensure and Inspection for Manufacturers and Distributors **(14-16)**
- 2. Pending or Possible Rulemaking Projects
- G. Implement 2021 Wisconsin Act 19 – Top 100 Most Prescribed Drugs – Discussion and Consideration (17-20)**
- H. Semaglutide/Tirzepatide Guidance Document Review – Discussion and Consideration (21)**
- I. Report from Pharmacy Consultant – Discussion and Consideration (22-23)**
- J. Speaking Engagements, Travel, or Public Relations Requests, and Reports (24)**
 - 1. Travel Report: MPJE State-Specific Review, September 16-18, 2026 – Mt. Prospect, IL, O'Hagan, and Wilson
 - 2. Travel Report: Executive Officers Forum and Member Forum, September 28 – October 1, 2026 – Mt. Prospect, IL, O'Hagan, and Wojciechowski
- K. Interdisciplinary Advisory Committee – Discussion and Consideration**
- L. Legislative and Policy Matters – Discussion and Consideration**
- M. Discussion and Consideration of Items Added After Preparation of Agenda**
 - 1. Introductions, Announcements and Recognition
 - 2. Administrative Matters
 - 3. Election of Officers
 - 4. Appointment of Liaisons and Alternates
 - 5. Delegation of Authorities
 - 6. Education and Examination Matters
 - 7. Credentialing Matters
 - 8. Practice Matters
 - 9. Administrative Rule Matters
 - 10. Legislative and Policy Matters
 - 11. Liaison Reports
 - 12. Board Liaison Training and Appointment of Mentors
 - 13. Informational Items
 - 14. Division of Legal Services and Compliance (DLSC) Matters
 - 15. Presentations of Petitions for Summary Suspension
 - 16. Petitions for Designation of Hearing Examiner
 - 17. Presentation of Stipulations, Final Decisions and Orders
 - 18. Presentation of Proposed Final Decisions and Orders
 - 19. Presentation of Interim Orders
 - 20. Pilot Program Matters
 - 21. Petitions for Re-Hearing
 - 22. Petitions for Assessments
 - 23. Petitions to Vacate Orders
 - 24. Requests for Disciplinary Proceeding Presentations
 - 25. Motions
 - 26. Petitions
 - 27. Appearances from Requests Received or Renewed
 - 28. Speaking Engagements, Travel, or Public Relation Requests, and Reports

N. Public Comments

CONVENE TO CLOSED SESSION to deliberate on cases following hearing (s. 19.85(1)(a), Stats.); to consider licensure or certification of individuals (s. 19.85(1)(b), Stats.); to consider closing disciplinary investigations with administrative warnings (ss. 19.85(1)(b), and 440.205, Stats.); to consider individual histories or disciplinary data (s. 19.85(1)(f), Stats.); and to confer with legal counsel (s. 19.85(1)(g), Stats.).

O. Credentialing Matters

1. Application Reviews

- a. C.J.H. – Renewal Application (IA-931626) **(25-120)**
- b. S.O. – Renewal Application (IA-944586) **(121-212)**
- c. C.S.R.K. – Pharmacy Exception Request **(213-237)**

P. Deliberation on Division of Legal Services and Compliance (DLSC) Matters

1. Proposed Stipulations, Final Decisions and Orders

- a. 23 PHM 183 and 24 PHM 0115 – Hallandale Pharmacy **(238-244)**
- b. 25 PHM 0206 – IHS Pharmacy **(245-250)**

2. Administrative Warnings

- a. 25 PHM 0032 – J.A.F. **(251-256)**
- b. 25 PHM 0058 – B.J.G. **(257-266)**
- c. 25 PHM 0058 – H.P. **(267-275)**
- d. 25 PHM 0058 – P.A.B. **(276-284)**
- e. 25 PHM 0058 – S.S. **(285-293)**

3. Case Closing(s)

- a. 23 PHM 129 – C.V.S., R.P. **(294-305)**
- b. 24 PHM 0045 & 24 PHM 0050 – W., J.S.H., and A.G.O. **(306-320)**
- c. 24 PHM 0105 – M.P. **(321-324)**
- d. 24 PHM 0173 – B.D.D.C. and B.D.D.C. **(325-328)**
- e. 25 PHM 0042 – M.B.H. **(329-334)**
- f. 25 PHM 0128 – S.P., S.P. **(335-339)**
- g. 25 PHM 0141 – O. **(340-344)**
- h. 25 PHM 0152 – P.C.P.W. **(345-350)**
- i. 25 PHM 0179 – W. **(351-353)**
- j. 26 PHM 0082 – R.W.F., F.F.S., G.G.M., and J.J.P. **(354-358)**
- k. 26 PHM 0091 – M.W.J. **(359-363)**

Q. Deliberation of Items Added After Preparation of the Agenda

1. Education and Examination Matters
2. Credentialing Matters
3. DLSC Matters
4. Monitoring Matters
5. Professional Assistance Procedure (PAP) Matters
6. Petitions for Summary Suspensions
7. Petitions for Designation of Hearing Examiner
8. Proposed Stipulations, Final Decisions and Orders
9. Proposed Interim Orders
10. Administrative Warnings
11. Review of Administrative Warnings
12. Proposed Final Decisions and Orders
13. Matters Relating to Costs/Orders Fixing Costs

14. Case Closings
15. Board Liaison Training
16. Petitions for Assessments and Evaluations
17. Petitions to Vacate Orders
18. Remedial Education Cases
19. Motions
20. Petitions for Re-Hearing
21. Appearances from Requests Received or Renewed

R. Consulting with Legal Counsel

RECONVENE TO OPEN SESSION IMMEDIATELY FOLLOWING CLOSED SESSION

S. Vote on Items Considered or Deliberated Upon in Closed Session, if Voting is Appropriate

T. Open Session Items Noticed Above Not Completed in the Initial Open Session

ADJOURNMENT

NEXT MEETING: DECEMBER 17, 2026

MEETINGS AND HEARINGS ARE OPEN TO THE PUBLIC, AND MAY BE CANCELLED WITHOUT NOTICE.

Times listed for meeting items are approximate and depend on the length of discussion and voting. All meetings are held virtually unless otherwise indicated. In-person meetings are typically conducted at 4822 Madison Yards Way, Madison, Wisconsin, unless an alternative location is listed on the meeting notice. To confirm a meeting or to request a complete copy of the board's agenda, please visit the Department website at <https://dsps.wi.gov>. The board may also consider materials or items filed after the transmission of this notice. Times listed for the commencement of any agenda item may be changed by the board for the convenience of the parties. The person credentialed by the board has the right to demand that the meeting at which final action may be taken against the credential be held in open session. Requests for interpreters for the hard of hearing, or other accommodations, are considered upon request by contacting the Affirmative Action Officer. Alternatively, reach the Meeting Staff by calling 608-267-7213.

**HYBRID (IN-PERSON/VIRTUAL)
PHARMACY EXAMINING BOARD
MEETING MINUTES
AUGUST 13, 2026**

PRESENT: Tiffany O'Hagan, Anthony Peterangelo (*Virtual*), Erick Sokn (*Virtual*), John Weitekamp, Christa Wilson (*Virtual*)

BSSENT: Paul Esser

STAFF: Brad Wojciechowski, Executive Director; Assistant Deputy Chief Legal Counsel, Renee Parton, Emily Constantine, Legal Counsel; Ashley Sarnosky, Board Administrative Specialist; and other Department staff

CALL TO ORDER

John Weitekamp, Chairperson, called the meeting to order at 11:03 a.m. A quorum was confirmed with five (5) members present.

ADOPTION OF AGENDA

MOTION: Tiffany O'Hagan moved, seconded by Anthony Peterangelo, to adopt the Agenda as published. Motion carried unanimously.

APPROVAL OF MINUTES OF JUNE 18, 2026

MOTION: Tiffany O'Hagan moved, seconded by Anthony Peterangelo, to approve the Minutes of June 18, 2026, as published. Motion carried unanimously.

INTRODUCTIONS, ANNOUNCEMENTS, AND RECOGNITION

Recognition: John Weitekamp, Pharmacist Member (Resigns: 8/13/2026)

MOTION: Tiffany O'Hagan moved, seconded by Anthony Peterangelo, to recognize and thank John Weitekamp for their years of dedicated service to the Board and State of Wisconsin. Motion carried unanimously.

ADMINISTRATIVE MATTERS

Election of Officers

Chairperson

NOMINATION: John Weitekamp nominated Tiffany O'Hagan for the Office of Chairperson. Tiffany O'Hagan accepted the nomination.

Brad Wojciechowski, Executive Director, called for nominations three (3) times.

Tiffany O'Hagan was elected as Chairperson by unanimous voice vote.

Vice Chairperson

NOMINATION: Tiffany O'Hagan nominated Anthony Peterangelo for the Office of Vice Chairperson. Anthony Peterangelo accepted the nomination.

Brad Wojciechowski, Executive Director, called for nominations three (3) times.

Anthony Peterangelo was elected as Vice Chairperson by unanimous voice vote.

Secretary

NOMINATION: Tiffany O'Hagan nominated Erick Sokn for the Office of Secretary. Erick Sokn accepted the nomination.

Brad Wojciechowski, Executive Director, called for nominations three (3) times.

Erick Sokn was elected as Secretary by unanimous voice vote.

ELECTION RESULTS	
Chairperson	Tiffany O'Hagan
Vice Chairperson	Anthony Peterangelo
Secretary	Erick Sokn

Appointment of Liaisons and Alternates

LIAISON APPOINTMENTS	
Credentialing Liaison(s)	Anthony Peterangelo, Tiffany O'Hagan, Christa Wilson
Education and Examinations Liaison(s)	Erick Sokn <i>Alternate: Vacant</i>
Monitoring Liaison(s)	Christa Wilson, Anthony Peterangelo <i>Alternate: Vacant</i>
Professional Assistance Procedure (PAP) Liaison(s)	Anthony Peterangelo <i>Alternate: Erick Sokn</i>
Travel Authorization Liaison(s)	<i>Vacant</i> <i>Alternate: Tiffany O'Hagan</i>
Legislative Liaison(s)	Anthony Peterangelo, Tiffany O'Hagan
Pilot Program Liaison(s)	Tiffany O'Hagan, Anthony Peterangelo

Newsletter Liaison(s)	Christa Wilson <i>Alternate: Vacant</i>
Website Liaison(s)	Christa Wilson
Appointed to Controlled Substances Board as per Wis. Stats. §15.405(5g)	Tiffany O'Hagan
PHARM Rep to SCAODA	Erick Sokn <i>Alternate: Vacant</i>
Variance Liaison(s)	Tiffany O'Hagan <i>Alternate: Anthony Peterangelo</i>
Inspection Liaison(s)	Erick Sokn <i>Alternate: Tiffany O'Hagan</i>
SCREENING PANEL APPOINTMENTS	
Screening Panel	Tiffany O'Hagan, Erick Sokn, Paul Esser <i>Alternate: Anthony Peterangelo</i>
COMMITTEE MEMBER APPOINTMENTS	
Pharmacy Rules Committee	Erick Sokn, Tiffany O'Hagan, Anthony Peterangelo
OTHER APPOINTMENTS	
Interdisciplinary Advisory Council	<i>Vacant</i> <i>Alternate: Christa Wilson</i>

CLOSED SESSION

MOTION: Tiffany O'Hagan moved, seconded by Erick Sokn, to convene to Closed Session to deliberate on cases following hearing (s. 19.85(1)(a), Stats.); to consider licensure or certification of individuals (s. 19.85(1)(b), Stats.); to consider closing disciplinary investigations with administrative warnings (ss. 19.85(1)(b), and 440.205, Stats.); to consider individual histories or disciplinary data (s. 19.85(1)(f), Stats.); and to confer with legal counsel (s. 19.85(1)(g), Stats.). John Weitekamp, Chairperson, read the language of the motion. The vote of each member was ascertained by voice vote. Roll Call Vote: Tiffany O'Hagan-yes; Erick Sokn-yes; Anthony Peterangelo-yes; John Weitekamp-yes; and Christa Wilson-yes. Motion carried unanimously.

The Board convened into Closed Session at 12:27 p.m.

CREDENTIALING MATTERS

Application Review

C.Z. – Initial Application (IA-907370)

MOTION: Tiffany O’Hagan moved, seconded by Erick Sokn, to approve the Initial Application IA-907370, once all requirements are met. Motion carried unanimously.

B.S.O. – Wholesale Distributor Applicant (IA-672656)

MOTION: John Weitekamp moved, seconded by Tiffany O’Hagan, to authorize Board Counsel to request additional information from Applicant IA-672656. Once the additional information is received the Chairperson may act on the application. Motion carried unanimously.

D.U.I.D.S. – Out-of-State Pharmacy (IA-691701)

MOTION: Tiffany O’Hagan moved, seconded by Anthony Peterangelo, to approve the Out-of-State Pharmacy application IA-691701, once all requirements are met. Motion carried unanimously.

E.C.S. – Initial Application (IA-852652)

MOTION: Erick Sokn moved, seconded by John Weitekamp, to authorize Board Counsel to request additional review from Pharmacy Consultant. Once the additional information is received, board member Erick Sokn may act on the application. Motion carried unanimously.

K.B. – Pharmacy Technician (IA-940749)

MOTION: Erick Sokn moved, seconded by Tiffany O’Hagan, to approve the Pharmacy Technician application of K.B., once all requirements are met. Motion carried unanimously.

**DELIBERATION ON DIVISION OF LEGAL SERVICES AND
COMPLIANCE (DLSC) MATTERS**

Administrative Warnings

25 PHM 0713 – P.J.S.

MOTION: Tiffany O’Hagan moved, seconded by Erick Sokn, to issue an Administrative Warning in the matter of P.J.S. DLSC Case Number 25 PHM 0713. Motion carried unanimously.

25 PHM 0181 – K.M.

MOTION: John Weitekamp moved, seconded by Tiffany O'Hagan, to issue an Administrative Warning in the matter of K.M., DLSC Case Number 25 PHM 0181. Motion carried unanimously.

Case Closings

MOTION: Tiffany O'Hagan moved, seconded by Erick Sokn, to close the following DLSC Cases for the reasons outlined below:

1. 23 PHM 146 – A.R. – No Violation
2. 24 PHM 0126 – C.M.M.P. – Prosecutorial Discretion
3. 25 PHM 0156 – W.P. – Insufficient Evidence
4. 25 PHM 0173 – H.X. – No Violation
5. 25 PHM 0181 – T.L.A. and W. – No Violation

Motion carried unanimously.

Proposed Stipulations, Final Decisions and Orders

25 PHM 0173 – CVS Pharmacy #8525

MOTION: Anthony Peterangelo moved, seconded by Tiffany O'Hagan, to adopt the Findings of Fact, Conclusions of Law and Order in the matter of disciplinary proceedings against CVS Pharmacy #8525, DLSC Case Number 25 PHM 0173. Motion carried unanimously.

MONITORING

Daniel VandeWalle – Modification Request

MOTION: Christa Wilson moved, seconded by Tiffany O'Hagan, to deny the request of Daniel VandeWalle for modification of the order but to allow internship hours to count towards the Pharmacy Technician experience requirement. **Reason for Denial:** Request is premature under paragraph 4 of the April 24, 2026, Order. Motion carried unanimously.

DELIBERATION ON PROPOSED FINAL DECISION AND ORDERS

Tiffany Sullivan, Respondent – (DHA Case Number SPS-25-0081/DLSC Case Number 25 PHM 0030)

MOTION: Christa Wilson moved, seconded by John Weitekamp, to delegate to DSPS Chief Legal Counsel the Board's authority to preside over disciplinary proceedings against Tiffany Sullivan, DHA Case Number SPS-25-0081/DLSC Case Number 25 PHM 0030. Motion carried unanimously.

RECONVENE TO OPEN SESSION

MOTION: Erick Sokn moved, seconded by Christa Wilson, to reconvene into Open Session. Motion carried unanimously.

The Board reconvened into Open Session at 2:06 p.m.

VOTING ON ITEMS CONSIDERED OR DELIBERATED UPON IN CLOSED SESSION

MOTION: Erick Sokn moved, seconded by Christa Wilson, to affirm all motions made and votes taken in Closed Session. Motion carried unanimously.

(Be advised that any recusals or abstentions reflected in the Closed Session motions stand for the purposes of the affirmation vote.)

ADJOURNMENT

MOTION: John Weitekamp moved, seconded by Anthony Peterangelo, to adjourn the meeting. Motion carried unanimously.

The meeting adjourned at 2:08 p.m.

**State of Wisconsin
Department of Safety & Professional Services**

AGENDA REQUEST FORM

1) Name and title of person submitting the request: Nilajah Hardin Administrative Rules Coordinator		2) Date when request submitted: 10/5/26 Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting										
3) Name of Board, Committee, Council, Sections: Pharmacy Examining Board												
4) Meeting Date: 10/15/26	5) Attachments: ☒ Yes ☐ No	6) How should the item be titled on the agenda page? Administrative Rule Matters – Discussion and Consideration 1. Scope Statement: a. Phar 1 and 6, Relating to Facilities, Floor Design, and Remodeling b. Phar 1 and 12 to 14, Relating to Licensure and Inspection for Manufacturers and Distributors 2. Pending or Possible Rulemaking Projects										
7) Place Item in: ☒ Open Session ☐ Closed Session	8) Is an appearance before the Board being scheduled? <i>(If yes, please complete Appearance Request for Non-DSPS Staff)</i> ☐ Yes ☒ No		9) Name of Case Advisor(s), if required: N/A									
10) Describe the issue and action that should be addressed: Attachments: 1. Phar 1 and 6 Scope Statement 2. Phar 1 and 12 to 14 Scope Statement 3. Rule Projects Chart Copies of current Board Rule Projects Can be Viewed Here: https://dsps.wi.gov/Pages/RulesStatutes/PendingRules.aspx												
<table style="width: 100%; border: none;"> <tr> <td style="width: 60%; border: none;">11) Authorization/</td> <td style="width: 40%; border: none;"></td> </tr> <tr> <td style="border: none;"> 10/5/26 Signature of person making this request Date </td> <td style="border: none;"></td> </tr> <tr> <td style="border: none;">Supervisor (if required)</td> <td style="border: none;">Date</td> </tr> <tr> <td colspan="2" style="border: none;"> Executive Director signature (indicates approval to add post agenda deadline item to agenda) </td> <td style="border: none;">Date</td> </tr> </table>				11) Authorization/		10/5/26 Signature of person making this request Date		Supervisor (if required)	Date	Executive Director signature (indicates approval to add post agenda deadline item to agenda)		Date
11) Authorization/												
10/5/26 Signature of person making this request Date												
Supervisor (if required)	Date											
Executive Director signature (indicates approval to add post agenda deadline item to agenda)		Date										
Directions for including supporting documents: 1. This form should be attached to any documents submitted to the agenda. 2. Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director. 3. If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.												

STATEMENT OF SCOPE

PHARMACY EXAMINING BOARD

Rule No.: Phar 1 and 6

Relating to: Facilities, Floor Design, and Remodeling

Rule Type: Permanent

1. Finding/nature of emergency (Emergency Rule only): N/A

2. Detailed description of the objective of the proposed rule: The objective of the proposed rule is to update and clarify rules concerning facilities, floor design, and remodeling for pharmacies. This may include revisions to Wis. Admin. Code chs. Phar 1 and 6.

3. Description of the existing policies relevant to the rule, new policies proposed to be included in the rule, and an analysis of policy alternatives:

Wisconsin Administrative Code ch. Phar 1 identifies the statutory authority for the adoption of the rules under Chapters Phar 1 to 19 of the Wisconsin Administrative Code, and contains definitions for certain terms used in Chapters Phar 1 to 19. Chapter Phar 6 contains rules regarding licensure, facilities, equipment, sanitation, and security for pharmacies. The board has identified a need to update and clarify the administrative code on these topics, including ensuring that the rules adequately address these subjects in the event of remodeling. The purpose is to protect public health, safety, and welfare and to ensure proper operation of pharmacies.

An alternative would be not to revise the code, which the board believes would continue a lack of clarity in the current regulations that could affect patient health, safety, and welfare and proper operation of pharmacies.

4. Detailed explanation of statutory authority for the rule (including the statutory citation and language):

Section 15.08 (5) (b), Stats., provides that an examining board “[s]hall promulgate rules for its own guidance and for the guidance of the trade or profession to which it pertains, and define and enforce professional conduct and unethical practices not inconsistent with the law relating to the particular trade or profession.”

Section 227.11 (2) (a), Stats., provides that “[e]ach agency may promulgate rules interpreting the provisions of any statute enforced or administered by the agency, if the agency considers it necessary to effectuate the purpose of the statute, but a rule is not valid if the rule exceeds the bounds of correct interpretation.”

Section 450.02 (2), Stats.: “[t]he board shall promulgate rules to do all of the following: (a) Define the active practice of pharmacy. The rules shall apply to all applicants for licensure under s. 450.05.”

Section 450.02 (3), Stats.: “[t]he board may promulgate rules: (a) Relating to the manufacture of drugs and the distribution and dispensing of prescription drugs.

(b) Establishing security standards for pharmacies.

(d) Necessary for the administration and enforcement of this chapter and ch. 961.

(e) Establishing minimum standards for the practice of pharmacy.”

Section 450.09 (4), Stats.: “[c]ondition of pharmacy. The pharmacy shall be maintained in a clean and orderly manner and the professional service area shall be equipped with proper fixtures and equipment for sanitation.”

5. Estimate of amount of time that state employees will spend developing the rule and of other resources necessary to develop the rule:

80 hours.

6. List with description of all entities that may be affected by the proposed rule:

Licensed pharmacies, pharmacists, registered pharmacy technicians, and their employers.

7. Summary and preliminary comparison with any existing or proposed federal regulation that is intended to address the activities to be regulated by the proposed rule: None.

8. Anticipated economic impact of implementing the rule (note if the rule is likely to have a significant economic impact on small businesses):

None to minimal. This rule is not likely to have a significant economic impact on small businesses.

Contact Person: Nilajah Hardin, Administrative Rules Coordinator, DSPSAdminRules@wisconsin.gov.

Approved for publication:

Approved for implementation:

Authorized Signature

Authorized Signature

Date Submitted

Date Submitted

STATEMENT OF SCOPE

PHARMACY EXAMINING BOARD

Rule No.: Phar 1 and 12 to 14

Relating to: Licensure and Inspection for Manufacturers and Distributors

Rule Type: Permanent

1. Finding/nature of emergency (Emergency Rule only): N/A

2. Detailed description of the objective of the proposed rule: The objective of the proposed rule is to update and clarify regulations on licensure and inspection for manufacturers and wholesale distributors of drugs and devices. This may include revisions to Wis. Admin. Code chs. Phar 1 and 12 to 14.

3. Description of the existing policies relevant to the rule, new policies proposed to be included in the rule, and an analysis of policy alternatives:

Wisconsin Administrative Code ch. Phar 1 identifies the statutory authority for the adoption of the rules under Chapters Phar 1 to 19 of the Wisconsin Administrative Code, and contains definitions for certain terms used in Chapters Phar 1 to 19. Chapter Phar 12 contains rules regarding licensure, inspections, and other matters for manufacturers of pharmacy products. Chapters Phar 13 contains rules regarding licensure, personnel, facility and security requirements, recordkeeping, and other matters for wholesale distributors of pharmacy products. Chapter 14 contains rules concerning applications for licensure and standards of professional conduct for home medical oxygen providers. The board has identified a need to update and clarify the administrative code on these topics. The purpose is to protect public health, safety, and welfare, to ensure proper operation of manufacturers and wholesale distributors, and to modernize and clarify these rules.

An alternative would be not to revise the code, which the board believes would continue gaps in the current rules that could affect patient health, safety, and welfare.

4. Detailed explanation of statutory authority for the rule (including the statutory citation and language):

Section 15.08 (5) (b), Stats., provides that an examining board “[s]hall promulgate rules for its own guidance and for the guidance of the trade or profession to which it pertains, and define and enforce professional conduct and unethical practices not inconsistent with the law relating to the particular trade or profession.”

Section 227.11 (2) (a), Stats., provides that “[e]ach agency may promulgate rules interpreting the provisions of any statute enforced or administered by the agency, if the agency considers it necessary to effectuate the purpose of the statute, but a rule is not valid if the rule exceeds the bounds of correct interpretation.”

Section 450.02 (3), Stats.: “[t]he board may promulgate rules: (a) Relating to the manufacture of drugs and the distribution and dispensing of prescription drugs.

(d) Necessary for the administration and enforcement of this chapter and ch. 961.”

Section 450.07 (4) (b), Stats.: “[t]he board shall adopt rules prescribing minimum standards for manufacturing and distributing drugs. Rules adopted under this paragraph may not impose requirements regarding the storage of a controlled substance in a safe, a steel cabinet, a vault, or any other secure storage compartment, area, room, or building unless one of the following applies:

1. The controlled substance is included in schedule I, II, III, or IV under ch. 961.
2. The controlled substance is also a controlled substance under federal law.
- (c) The rules adopted by the board under par. (b) shall require a manufacturer to maintain and to update at least once per month a list of the manufacturer's authorized distributors of record."

Section 450.071 (1), Stats.: "[n]o person may engage in the wholesale distribution of a prescription drug in this state without obtaining a license from the board for each facility from which the person distributes prescription drugs. The board shall exempt a manufacturer that distributes prescription drugs or devices manufactured by the manufacturer from licensing and other requirements under this section to the extent the license or requirement is not required under federal law or regulation, unless the board determines that it is necessary to apply a requirement to a manufacturer."

(4) The board may set, by rule, continuing education requirements for designated representatives under this section."

Section 450.073, (3), Stats.: "[t]he board shall promulgate rules implementing an electronic track and trace pedigree system. Not later than July 1, 2010, the board shall determine the date on which the system will be implemented. The system may not be implemented before July 1, 2011, and the board may delay the implementation date in increments if the board determines that the technology to implement the system is not yet universally available across the prescription drug supply chain or is not capable of adequately protecting patient safety."

Section 450.076, Stats.: "[h]ome medical oxygen providers; licensure. (4) The board shall promulgate rules implementing this section. The rules shall include rules governing the professional conduct of licensed providers and their employees and agents."

5. Estimate of amount of time that state employees will spend developing the rule and of other resources necessary to develop the rule:

80 hours.

6. List with description of all entities that may be affected by the proposed rule:

Licensed pharmacies, pharmacists, registered pharmacy technicians, their employers, licensed manufacturers and distributors of pharmacy products, and licensed home medical oxygen providers.

7. Summary and preliminary comparison with any existing or proposed federal regulation that is intended to address the activities to be regulated by the proposed rule:

The practice of pharmacy is not regulated by the federal government and Wisconsin has its own controlled substances schedules. However, the federal government does regulate federally controlled substances and the vast majority of Wisconsin controlled substances are also federally controlled substances. Title 21 CFR Chapter II governs federally scheduled controlled substances, including: remote dispensing; registration of manufacturers, distributors and dispensers of controlled substances; prescriptions; orders for schedule I and II controlled substances; requirements for electronic orders and prescriptions; and disposal.

8. Anticipated economic impact of implementing the rule (note if the rule is likely to have a significant economic impact on small businesses):

None to minimal. This rule is not likely to have a significant economic impact on small businesses.

Contact Person: Nilajah Hardin, Administrative Rules Coordinator, DSPSAdminRules@wisconsin.gov.

Approved for publication:

Approved for implementation:

Authorized Signature

Authorized Signature

Date Submitted

Date Submitted

**Pharmacy Examining Board
Rule Projects (updated 10/5/26)**

CH Rule Number	Scope Number	Scope Expiration Date	Code Chapter Affected	Relating Clause	Stage of Rule Process	Next Step
Not Assigned Yet	Not Assigned Yet	TBD	Phar 1 and 7	Patient Drug Information Monographs	Scope Statement tabled at 10/16/25 Meeting	TBD
Not Assigned Yet	Not Assigned Yet	TBD	Phar 1, 5, 6, 7, 8, 10, 15, and 19	Remote Dispensing Sites	Drafting	Board Review of Preliminary Rule Draft
Not Assigned Yet	Not Assigned Yet	TBD	Phar 1 and 6	Facilities, Floor Design, and Remodeling	Scope Statement Reviewed at 10/15/26 Meeting	Governor's Office Approval and Submission for Publication
Not Assigned Yet	Not Assigned Yet	TBD	Phar 1 and 12 to 14	Licensure and Inspection for Manufacturers and Distributors	Scope Statement Reviewed at 10/15/26 Meeting	Governor's Office Approval and Submission for Publication
25-073	089-24	05/05/2027	Phar 7	Electronic Prescriptions, Prescription Labeling, CPR for Pharmacists, Epinephrine Delivery Systems, Controlled Substance Prescription Transfers, Remote Dispensing, Managing Pharmacist Definition, Initial Consultation, Alteration, and Final Check	Final Rule Draft Submitted to Governor on 9/28/26	Submission Legislature, Adoption, and Publication

**State of Wisconsin
Department of Safety & Professional Services**

AGENDA REQUEST FORM

1) Name and title of person submitting the request: Brad Wojciechowski, Executive Director		2) Date when request submitted: 9/30/2026 Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting	
3) Name of Board, Committee, Council, Sections: Pharmacy Examining Board			
4) Meeting Date: 10/15/2026	5) Attachments: ☒ Yes ☐ No	6) How should the item be titled on the agenda page? Implement 2021 Wisconsin Act 19 – Top 100 Most Prescribed Drugs – Discussion and Consideration	
7) Place Item in: ☒ Open Session ☐ Closed Session	8) Is an appearance before the Board being scheduled? <i>(If yes, please complete Appearance Request for Non-DSPS Staff)</i> ☐ Yes <Appearance Name(s)> ☐ No	9) Name of Case Advisor(s), if applicable: <Click Here to Add Case Advisor Name or N/A>	
10) Describe the issue and action that should be addressed: Review 2025 Top 100 Drug List as published January 1, 2026. The Board will review and make a motion to designate a member to review and approve updated list.			
11) Authorization  Signature of person making this request 9/30/2026 Date Supervisor (Only required for post agenda deadline items) Date Executive Director signature (Indicates approval for post agenda deadline items) Date			
Directions for including supporting documents: 1. This form should be saved with any other documents submitted to the Agenda Items folders. 2. Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director. 3. If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.			

John Weitekamp
Chairperson

Tiffany O'Hagan
Vice Chairperson

Anthony Peterangelo
Secretary

PHARMACY EXAMINING BOARD



4822 Madison Yards Way
PO Box 8366
Madison WI 53708-8366

Email: dsps@wisconsin.gov
Voice: 608-266-2112
FAX: 608-251-3032

*** PUBLIC NOTICE *** Under Wis. Stats. s. 450.13 (5m) (a), the Pharmacist may substitute a less expensive drug product equivalent, unless the consumer or prescribing practitioner have indicated otherwise.

*** PUBLIC NOTICE *** Under Wis. Stats. s. 450.135 (8m), the Pharmacist may substitute a less expensive interchangeable biological product, unless the consumer or prescribing practitioner have indicated otherwise. The public may access a full list of interchangeable biological products that have been approved by the Food and Drug Administration (FDA) here: <https://www.fda.gov/drugs/biosimilars/biosimilar-product-information>

*** PUBLIC NOTICE *** Under Wis. Stats. s. 450.13 (5m) (b), each pharmacy must provide notice to the public on how it may access the Pharmacy Examining Board's list of the 100 most commonly prescribed generic drug product equivalents. The public may access this list here: <https://dsps.wi.gov/Pages/BoardsCouncils/Pharmacy/Default.aspx>

TOP 100 DRUGS A TO Z BRAND NAME

BRAND NAME	DRUG GENERIC NAME	QUANTITY
ABILIFY	ARIPIRAZOLE 10MG TABLET	30
ADVAIR DISKUS	FLUTICASONE PROPIONATE/SALMETEROL DISKUS	60
AMARYL	GLIMEPIRIDE 2MG TABLET	30
AMOXIL	AMOXICILLIN 500MG CAPSULE	30
ARICEPT	DONEPEZIL 10MG TABLET	30
AUGMENTIN	AMOX TR-K CLAV 875-125 MG TABLET	20
AVAPRO	IRBESARTAN 150MG	30
BACTRIM DS	SULFAMETH/TRIMETH DS TABLET	20
BACTROBAN	MUPIROCIN OINTMENT	22 GRAM
BENICAR	OLMESARTAN 20MG TABLET	30
CATAPRES	CLONIDINE 0.1MG TABLET	90
CELEBREX	CELECOXIB 200MG CAPSULE	30
CELEXA	CITALOPRAM 20MG TABLET	30
CIPRO	CIPROFLOXACIN 500MG TABLET	20
COREG	CARVEDILOL 6.25MG TABLET	60
COUMADIN	WARFARIN 5MG TABLET	30
COZAAR	LOSARTAN 50MG TABLET	30
CRESTOR	ROSUVASTATIN 10MG TABLET	30
CYMBALTA	DULOXETINE 30MG CAPSULE	30
DELTASONE	PREDNISONE 10MG TABLET	30
DELTASONE	PREDNISONE 20MG TABLET	30
DEPAKOTE	DIVALPROEX 500MG EC TABLET	90
DESYREL	TRAZODONE 50MG TABLET	30

DIFLUCAN	FLUCONAZOLE 150MG TABLET	1
DILANTIN	PHENYTOIN SOD EXT 100 MG CAPSULE	90
DIOVAN	VALSARTAN 80MG TABLET	30
EFFEXOR XR	VENLAFAXINE XR 75MG CAPSULE	30
ELIQUIS	APIXABAN 5MG TABLET	30
FLAGYL	METRONIDAZOLE 500MG TABLET	20
FLEXERIL	CYCLOBENZAPRINE 10MG TABLET	30
FLOMAX	TAMSULOSIN 0.4MG CAPSULE	30
FLONASE	FLUTICASONE 50MCG NASAL	16 GRAM
FLOVENT HFA	FLUTICASONE HFA 110MCG INHALER	12 GRAM
FOLVITE	FOLIC ACID 1MG TABLET	30
FOSAMAX	ALENDRONATE 70MG TABLET	4
GLUCOPHAGE	METFORMIN HCL 1,000 MG TABLETLET	60
GLUCOPHAGE	METFORMIN HCL 500 MG TABLETLET	60
GLUCOPHAGE XR	METFORMIN ER 500MG TABLET	60
GLUCOTROL XL	GLIPIZIDE ER 10MG TABLET	30
GLUCOTROL XL	GLIPIZIDE ER 5MG TABLET	30
HYDRODIURIL	HYDROCHLOROTHIAZIDE 12.5MG CAPSULE	30
HYDRODIURIL	HYDROCHLOROTHIAZIDE 25MG TABLET	30
IMITREX	SUMATRIPTAN 100MG TABLET	9
JANUVIA	SITAGLIPTAN 100MG TABLET	30
K-DUR	POTASSIUM 20MEQ TABLET	30
KEFLEX	CEPHALEXIN 500MG CAPSULE	28
LAMICTAL	LAMOTRIGINE 25MG TABLET	30
LAMISIL	TERBINAFINE 250MG TABLET	30
LASIX	FUROSEMIDE 20MG TABLET	30
LASIX	FUROSEMIDE 40MG TABLET	30
LEXAPRO	ESCITALOPRAM 10MG TABLET	30
LIPITOR	ATORVASTATIN 10MG TABLET	30
LIPITOR	ATORVASTATIN 20MG TABLET	30
LOPRESSOR	METOPROLOL 50MG TABLET	60
LYRICA	PREGABALIN 50MG CAPSULE	60
MACROBID	NITROFURANTOIN MONO 100MG CAPSULE	14
MAXZIDE	TRIAMTERENE/HCTZ 37.5MG TABLET	30
MOBIC	MELOXICAM 15MG TABLET	30
MOTRIN	IBUPROFEN 600MG TABLET	90
MOTRIN	IBUPROFEN 800MG TABLET	90
NAPROSYN	NAPROXEN 500MG TABLET	60
NEURONTIN	GABAPENTIN 300MG CAPSULE	90
NEXIUM	ESOMEPRAZOLE 40MG CAPSULE	30
NORVASC	AMLODIPINE 10MG TABLET	30
PAXIL	PAROXETINE 20MG TABLET	30
PLAVIX	CLOPIDOGREL 75MG TABLET	30
PRAVACHOL	PRAVASTATIN 20MG TABLET	30
PRILOSEC	OMEPRAZOLE 20MG CAPSULE	30
PROCARDIA XL	NIFEDIPINE ER 30MG TABLET	30
PROSCAR	FINASTERIDE 5MG TABLET	30
PROTONIX	PANTOPRAZOLE 40MG TABLET	30
PROZAC	FLUOXETINE 20MG CAPSULE	30
RISPERDAL	RISPERIDONE 1MG TABLET	30
SEROQUEL	QUETIAPINE 100MG TABLET	30

SINGULAIR	MONTELUKAST SOD 10 MG TABLET	30
SYNTHROID	LEVOTHYROXINE 100MCG	30
SYNTHROID	LEVOTHYROXINE 50MCG	30
TENORMIN	ATENOLOL 25MG TABLET	30
TENORMIN	ATENOLOL 50MG TABLET	30
TOPAMAX	TOPIRAMATE 50MG TABLET	30
TOPROL XL	METOPROLOL XL 50MG TABLET	30
TRICOR	FENOFIBRATE 145MG TABLET	30
V-CILLIN-K	PENICILLIN -VK 500MG TABLET	40
VALTREX	VALACYCLOVIR 500MG TABLET	30
VASOTEC	ENALAPRIL 10MG TABLET	30
VENTOLIN INHALER	ALBUTEROL HFA INHALER	18 GRAM
VIBRAMYCIN	DOXYCYCLINE 100MG CAPSULE	30
WELLBUTRIN SR	BUPROPION SR 150MG TABLET	60
XALATAN	LATANOPROST 0.005% DROPS	2.5 ML
XARELTO	RIVAROXABAN 20MG TABLET	30
ZESTORETIC	LISINOPRIL/HCTZ 20/12.5MG	30
ZESTRIL	LISINOPRIL 10MG TABLET	30
ZESTRIL	LISINOPRIL 20MG TABLET	30
ZETIA	EZETIMIBE 10MG TABLET	30
ZITHROMAX	AZITHROMYCIN 250MG TABLET	6
ZOCOR	SIMVASTATIN 20MG TABLET	30
ZOCOR	SIMVASTATIN 40MG TABLET	30
ZOLOFT	SERTRALINE 100MG TABLET	30
ZOLOFT	SERTRALINE 50MG TABLET	30
ZYLOPRIM	ALLOPURINOL 100MG TABLET	30
ZYPREXA	OLANZAPINE 5MG TABLET	30

**State of Wisconsin
Department of Safety & Professional Services**

AGENDA REQUEST FORM

1) Name and title of person submitting the request: Brad Wojciechowski, Executive Director		2) Date when request submitted: 10/1/2026 Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting	
3) Name of Board, Committee, Council, Sections: Pharmacy Examining Board			
4) Meeting Date: 10/15/2026	5) Attachments: ☐ Yes ☒ No	6) How should the item be titled on the agenda page? Semaglutide/Tirzepatide Guidance Document Review – Discussion and Consideration	
7) Place Item in: ☒ Open Session ☐ Closed Session	8) Is an appearance before the Board being scheduled? <i>(If yes, please complete Appearance Request for Non-DSPS Staff)</i> ☐ Yes <Appearance Name(s)> ☐ No	9) Name of Case Advisor(s), if applicable: <Click Here to Add Case Advisor Name or N/A>	
10) Describe the issue and action that should be addressed:			
11) Authorization  10/1/2026 Signature of person making this request Date Supervisor (Only required for post agenda deadline items) Date Executive Director signature (Indicates approval for post agenda deadline items) Date			
Directions for including supporting documents: 1. This form should be saved with any other documents submitted to the Agenda Items folders. 2. Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director. 3. If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.			


**State of Wisconsin
Department of Safety & Professional Services**

AGENDA REQUEST FORM

1) Name and title of person submitting the request: Brad Wojciechowski, Executive Director		2) Date when request submitted: 10/2/2026 Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting	
3) Name of Board, Committee, Council, Sections: Pharmacy Examining Board			
4) Meeting Date: 10/15/2026	5) Attachments: ☒ Yes ☐ No	6) How should the item be titled on the agenda page? Report from Pharmacy Consultant– Discussion and Consideration	
7) Place Item in: ☒ Open Session ☐ Closed Session	8) Is an appearance before the Board being scheduled? <i>(If yes, please complete Appearance Request for Non-DSPS Staff)</i> ☐ Yes <Appearance Name(s)> ☐ No		9) Name of Case Advisor(s), if applicable: <Click Here to Add Case Advisor Name or N/A>
10) Describe the issue and action that should be addressed:			
11) Authorization  Signature of person making this request 10/2/2026 Date Supervisor (Only required for post agenda deadline items) Date Executive Director signature (Indicates approval for post agenda deadline items) Date			
Directions for including supporting documents: 1. This form should be saved with any other documents submitted to the Agenda Items folders. 2. Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director. 3. If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.			

Multistate Inspection Blueprint Program | NABP

- Voluntary program that assists states interested in standardized inspection processes.
- Two blueprints available – sterile compounding and distribution inspection (in Jan 2027).
- Provided at no cost to participating states
- Training provided every 12 months at no cost
- Provides structured approach to inspection of sterile compounding facilities and distributors with validated inspection tool
- Must inspect resident sterile compounding pharmacies that ship across state lines at least once every 18 months – this will require commitment to identify pharmacies that do sterile compounding and ship across state lines
- Provides access to the NABP inspection sharing network
- Program is designed with public health as primary concern, ensuring that inspections identify and address deficiencies.



Current Pharmacy Inspection Blueprint States

**State of Wisconsin
Department of Safety & Professional Services**

AGENDA REQUEST FORM

1) Name and title of person submitting the request: Brad Wojciechowski, Executive Director		2) Date when request submitted: 10/1/2026 Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting	
3) Name of Board, Committee, Council, Sections: Pharmacy Examining Board			
4) Meeting Date: 10/15/2026	5) Attachments: ☐ Yes ☒ No	6) How should the item be titled on the agenda page? Speaking Engagements, Travel, or Public Relation Requests, and Reports – Discussion and Consideration 1) Travel Report: MPJE State-Specific Review, September 16-18, 2026 – Mt. Prospect, IL, O'Hagan, and Wilson 2) Travel Report: Executive Officers Forum and Member Forum, September 28 – October 1, 2026 – Mt. Prospect, IL, O'Hagan, and Wojciechowski	
7) Place Item in: ☒ Open Session ☐ Closed Session	8) Is an appearance before the Board being scheduled? <i>(If yes, please complete Appearance Request for Non-DSPS Staff)</i> ☐ Yes <Appearance Name(s)> ☐ No	9) Name of Case Advisor(s), if applicable: <Click Here to Add Case Advisor Name or N/A>	
10) Describe the issue and action that should be addressed:			
11) Authorization  Signature of person making this request 6/15/2026 Date Supervisor (Only required for post agenda deadline items) Date Executive Director signature (Indicates approval for post agenda deadline items) Date			
Directions for including supporting documents: 1. This form should be saved with any other documents submitted to the Agenda Items folders. 2. Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director. 3. If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.			